Genmab A/S (GNMSF) FDA Approvals

Genmab A/S logo
$515.00 -0.53 (-0.10%)
As of 09:31 AM Eastern

Genmab A/S's Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Genmab A/S (GNMSF). Over the past two years, Genmab A/S has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Rina-S and epcoritamab. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Rina-S FDA Regulatory Events

Rina-S is a drug developed by Genmab A/S for the following indication: In Heavily Pretreated Patients with Ovarian and Endometrial Cancers. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Epcoritamab FDA Regulatory Events

Epcoritamab is a drug developed by Genmab A/S for the following indication: To-Treat Relapsed/Refractory Follicular Lymphoma. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Genmab A/S FDA Events - Frequently Asked Questions

In the past two years, Genmab A/S (GNMSF) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Genmab A/S (GNMSF) has reported FDA regulatory activity for the following drugs: Rina-S and epcoritamab.

The most recent FDA-related event for Genmab A/S occurred on October 23, 2026, involving Rina-S. The update was categorized as "Top-line results," with the company reporting: "Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC) regardless of FRα expression level or prior treatment with mirvetuximab."

Current therapies from Genmab A/S in review with the FDA target conditions such as:

  • In Heavily Pretreated Patients with Ovarian and Endometrial Cancers - Rina-S
  • To-Treat Relapsed/Refractory Follicular Lymphoma - epcoritamab
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for OTCMKTS:GNMSF last updated on 10/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners